Contains Nonbinding Recommendations

Draft – Not for Implementation

Draft Guidance on Deferiprone

November 2022

This draft guidance, when finalized, will represent the current thinking of the Food and Drug Administration (FDA, or the Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the Office of Generic Drugs.

In general, FDA's guidance documents do not establish legally enforceable responsibilities. Instead, guidances describe the Agency's current thinking on a topic and should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the word *should* in Agency guidances means that something is suggested or recommended, but not required.

Active Ingredient: Deferiprone

Dosage Form; Route: Tablet; oral

Recommended Studies: Two in vivo bioequivalence studies with pharmacokinetic endpoints

1. Type of study: Fasting
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 1000 mg
   Subjects: Healthy males and healthy females not of reproductive potential
   Additional comments: The study drug products should be administered with intact tablets. Male subjects with female partners of reproductive potential should use effective contraception during the study and for 3 months after the last dose.

2. Type of study: Fed
   Design: Single-dose, two-treatment, two-period crossover in vivo
   Strength: 1000 mg
   Subjects: Healthy males and healthy females not of reproductive potential
   Additional comments: See comments above.

Analyte to measure: Deferiprone in plasma or serum

Bioequivalence based on (90% CI): Deferiprone

Waiver request of in vivo testing: Not applicable

Dissolution test method and sampling times: The dissolution information for this drug product can be found in the FDA's Dissolution Methods database, http://www.accessdata.fda.gov/scripts/cder/dissolution/. Conduct comparative dissolution testing on 12 dosage units for each of the test and reference products. Specifications will be determined upon evaluation of the Abbreviated New Drug Application (ANDA).

If the strength of the tablet product has a functional score, additional dissolution profile testing should be conducted for each segment of the split tablet after manual and mechanical splitting as per the most recent version of the FDA guidance for industry on *Tablet Scoring: Nomenclature, Labeling, and Data for Evaluation*.[a]

Unique Agency Identifier: PSG_212269

[a] For the most recent version of a guidance, check the FDA guidance web page at https://www.fda.gov/regulatory-information/search-fda-guidance-documents.